Nuciferine

Pharmacology & Research

Nuciferine is an aporphine alkaloid that concentrates in the leaf of sacred lotus (Nelumbo nucifera) and appears, variably, in blue lotus (Nymphaea). Its most rigorous characterisation is receptor pharmacology: a full NIMH-PDSP screen defined an “aripiprazole-like” polypharmacology — dopamine D2-family partial agonism, 5-HT2A/2C antagonism, 5-HT1A agonism and dopamine-transporter inhibition — with matching in-vivo signatures (it blocked the DOI head-twitch and substituted for clozapine in mice) ^{1Reference 1Farrell MS et al. · 2016In-vitro and in-vivo characterisation of the alkaloid nuciferineView study →}. This is the real basis behind blue-lotus “relaxant/euphoric” lore — but two facts undercut the folk reputation: oral bioavailability is very low (~2% in rats) ^{10Reference 102018AnimalPharmacokinetics, tissue distribution, bioavailability and excretion of nuciferine in ratsView study →}, and authentic blue-lotus flowers often contain near-zero nuciferine while processed “resins” carry far more ^{12Reference 12Poklis JL et al. · 2017Blue-lotus resin in e-cigarettes: nuciferine contentView study →}, so product effects may not even be nuciferine-driven.

1. CNS / receptor pharmacology

The real basis for the lotus “relaxant” reputation. A full NIMH-PDSP screen defined nuciferine’s polypharmacology — D2-family partial agonism, 5-HT2A/2C antagonism, 5-HT1A agonism, DAT inhibition — and in mice it blocked the DOI head-twitch and substituted for the clozapine discriminative cue, both atypical-antipsychotic-like signatures ^{1Reference 1Farrell MS et al. · 2016In-vitro and in-vivo characterisation of the alkaloid nuciferineView study →}, as synthesised in a 2026 review ^{2Reference 22026ReviewInsights into nuciferine: a natural multifunctional bioactive alkaloid (review)View study →}.

Gap: the recreational psychoactivity of blue lotus is overwhelmingly traditional/anecdotal — there is no controlled human dosing or human PK/PD, and authentic flower material often contains near-zero nuciferine, so product effects may not be nuciferine-driven ^{1,12Reference 1Farrell MS et al. · 2016In-vitro and in-vivo characterisation of the alkaloid nuciferineView study →Reference 12Poklis JL et al. · 2017Blue-lotus resin in e-cigarettes: nuciferine contentView study →}.

2. Metabolic / anti-obesity

The most consistent efficacy signal. Nuciferine reduced adiposity and weight gain in high-fat-diet rats via gut-microbiota modulation ^{3Reference 32020AnimalNuciferine modulates the gut microbiota and prevents obesity in high-fat-diet-fed ratsView study →}, improved intestinal-barrier permeability through autophagy ^{4Reference 42021Nuciferine improves high-fat-diet-induced obesity by reducing intestinal permeability through autophagyView study →}, and engaged an AMPK→FAS/HSL axis in liver and fat ^{5Reference 52022AMPK-mediated FAS/HSL pathway in nuciferine’s effect on obesity and hepatic steatosisView study →}.

Gap: all rodent, at doses (often 10–50 mg/kg) that do not translate given ~2% oral bioavailability, with no human trial ^{3,5Reference 32020AnimalNuciferine modulates the gut microbiota and prevents obesity in high-fat-diet-fed ratsView study →Reference 52022AMPK-mediated FAS/HSL pathway in nuciferine’s effect on obesity and hepatic steatosisView study →}.

3. Anti-inflammatory / renal

Nuciferine restored potassium-oxonate-induced hyperuricemia and dampened kidney inflammation ^{8Reference 82015AnimalNuciferine restores potassium-oxonate-induced hyperuricemia and kidney inflammation in miceView study →}, and alleviated renal injury by inhibiting inflammatory responses in fructose-fed rats ^{9Reference 92016AnimalNuciferine alleviates renal injury by inhibiting inflammation in fructose-fed ratsView study →}.

Gap: a narrow model set, with mechanism largely cytokine-level and associative, and preclinical only ^{8,9Reference 82015AnimalNuciferine restores potassium-oxonate-induced hyperuricemia and kidney inflammation in miceView study →Reference 92016AnimalNuciferine alleviates renal injury by inhibiting inflammation in fructose-fed ratsView study →}.

4. Hepatoprotective

Nuciferine ameliorated hepatic steatosis in high-fat-diet/STZ diabetic mice via PPARα/PPARγ modulation ^{6Reference 62018AnimalNuciferine ameliorates hepatic steatosis in high-fat-diet/STZ diabetic mice via PPARα/PPARγView study →} and regulated hepatic lipid metabolism in diabetic rats ^{7Reference 72019AnimalNuciferine prevents hepatic steatosis by regulating lipid metabolism in diabetic ratsView study →}.

Gap: heavily overlapping with the metabolic story (same HFD/diabetic paradigms), with no isolated human liver endpoint ^{6,7Reference 62018AnimalNuciferine ameliorates hepatic steatosis in high-fat-diet/STZ diabetic mice via PPARα/PPARγView study →Reference 72019AnimalNuciferine prevents hepatic steatosis by regulating lipid metabolism in diabetic ratsView study →}.

5. Antidiabetic

A 2026 study reported improved cognitive impairment and insulin resistance in type-2-diabetic rodents by targeting the insulin receptor ^{11Reference 112026Nuciferine ameliorates cognitive impairment and insulin resistance in T2DM via the insulin receptorView study →}.

Gap: the newest and least-replicated claim — a single primary study whose direct insulin-receptor mechanism needs independent confirmation ^{11Reference 112026Nuciferine ameliorates cognitive impairment and insulin resistance in T2DM via the insulin receptorView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Dopamine D2 / D5 (partial agonist), D4 (agonist), DAT (inhibitor)	atypical-antipsychotic-like / anti-addiction profile	CNS
5-HT2A/2B/2C (antagonist), 5-HT1A (agonist), 5-HT6/7	serotonergic modulation; blocks head-twitch	CNS
AMPK → FAS / HSL	↓ lipogenesis, ↑ lipolysis	anti-obesity, hepatic lipid
PPARα / PPARγ	modulation	hepatic steatosis
Gut microbiota / intestinal barrier (autophagy)	remodelled/restored	anti-obesity
Insulin receptor	reported targeting	insulin resistance

Pharmacokinetics

The single most important translational caveat: nuciferine’s absolute oral bioavailability is ~1.9% in rats (10 mg/kg oral versus IV), i.e. poor absorption into the systemic circulation ^{10Reference 102018AnimalPharmacokinetics, tissue distribution, bioavailability and excretion of nuciferine in ratsView study →}. It distributes rapidly and widely — tissue exposure ranks kidney > lung > spleen > liver > brain > heart, so it does cross into the brain (consistent with its CNS activity) — and roughly half an oral dose is excreted renally as parent drug ^{10Reference 102018AnimalPharmacokinetics, tissue distribution, bioavailability and excretion of nuciferine in ratsView study →}. All pharmacokinetics are rodent; there is no human data. And because blue-lotus consumer products (vape “resins,” teas) vary wildly in nuciferine content — often near-zero in authentic flowers, elevated in processed material — real-world exposure cannot be framed as a reliable “dose” ^{12,13Reference 12Poklis JL et al. · 2017Blue-lotus resin in e-cigarettes: nuciferine contentView study →Reference 13Dosoky NS et al. · 2023Chemical composition, market survey and safety assessment of blue lotusView study →}.

Clinical trials

There are no controlled human trials of isolated nuciferine for any indication. The only human-relevant data are analytical surveys of blue-lotus consumer products ^{12,13Reference 12Poklis JL et al. · 2017Blue-lotus resin in e-cigarettes: nuciferine contentView study →Reference 13Dosoky NS et al. · 2023Chemical composition, market survey and safety assessment of blue lotusView study →}, not dosing studies; all efficacy evidence is preclinical.

Last checked: July 2026.

Toxicity & Safety

The isolated compound’s human safety is uncharacterised, and preclinical direct-toxicity signals are mild — so the moderate flag rests mainly on its CNS receptor activity, brain penetration and real-world unregulated recreational exposure, not on documented organ toxicity. The recreational context is itself a hazard: nuciferine is the cited psychoactive marker of blue-lotus vapes and teas, but content is wildly variable and often near-zero in authentic flowers while elevated in processed “resins,” so consumers cannot dose reliably and marketed effects may stem from other constituents or adulterants ^{12,13Reference 12Poklis JL et al. · 2017Blue-lotus resin in e-cigarettes: nuciferine contentView study →Reference 13Dosoky NS et al. · 2023Chemical composition, market survey and safety assessment of blue lotusView study →}. The interaction profile is theoretical, from its receptor pharmacology: dopaminergic (D2 partial agonism could interact with antipsychotics, dopamine agonists and antiemetics), serotonergic (5-HT1A/5-HT2 activity with SSRIs/SNRIs, triptans and other serotonergic agents), and additive sedation with CNS depressants — none observed clinically.

Pregnancy & lactation

Avoid. There is no reproductive or developmental toxicology data, and a CNS-penetrant, brain-distributing dopamine/serotonin-receptor-active alkaloid with no established safety margin should be treated as contraindicated in pregnancy and lactation.

Dosage

There is no established human dose, and none should be stated. Preclinical reference only (not for human extrapolation): rodent efficacy typically uses ~10–50 mg/kg/day orally, and the pharmacokinetic study used 10 mg/kg — but given ~2% oral bioavailability, naive body-surface conversion is not meaningful ^{10Reference 102018AnimalPharmacokinetics, tissue distribution, bioavailability and excretion of nuciferine in ratsView study →}. Real-world blue-lotus exposure is unquantifiable due to product variability and cannot be framed as a dose ^{13Reference 13Dosoky NS et al. · 2023Chemical composition, market survey and safety assessment of blue lotusView study →}.

References